Company Profile
Bangkok Genomics Innovation Public provides medical analysis services in Thailand. The company offers screening for fetal chromosomal abnormalities using non-invasive prenatal testing under the NIFTY brand, preimplantation chromosomal abnormality and thalassemia carrier gene screening, infectious disease group analysis, and monkeypox virus analysis
Other screening tests, such as cancer-related gene screening to predict the risk of inherited cancer, monitor treatment, select drugs that are appropriate for one's genetics, and provide treatment and disease prevention. Additionally, it offers genetic analysis using whole exome sequencing, a technology that can detect gene abnormalities that cause diseases.
Its portfolio also includes individual genetic decoding, which involves detailed genetic sequencing to analyze genetic information and identify aspects such as ethnicity or ancestry, optimal exercise profiles, metabolic capabilities, and the risk of genetic diseases, newborn screening, and health check-ups for various needs.
It also supports research services in both medical and fields, offers DNA and RNA sequencing, metabolomics and proteomics services, and medical products comprising genetic sequencers.
Its portfolio also includes NIPT, PGT-A, hereditary cancer screening, and precision oncology solutions, real-time PCR that includes beta thalassemia genotyping and human papillomavirus genotyping kits, and cell-free DNA storage tubes.
The company serves government sectors such as medical schools and health centers Private sectors such as clinics, hospitals, private medical laboratories, research institutes, and universities. Founded in 2017, Bangkok Genomics Innovation Public is headquartered in Bangkok, Thailand.